US 11,963,979 B2
Process for T cell expansion
Rainer Ludwig Knaus, London (GB); Katy Rebecca Newton, London (GB); Juan Vera, Houston, TX (US); Ann Leen, Houston, TX (US); Cliona Rooney, Bellaire, TX (US); and John R. Wilson, New Brighton, MN (US)
Assigned to AlloVir, Inc., Waltham, MA (US); Baylor College of Medicine, Houston, TX (US); and Wilson Wolf Manufacturing Corporation, New Brighton, MN (US)
Filed by AlloVir, Inc., Waltham, MA (US); Baylor College of Medicine, Houston, TX (US); and Wilson Wolf Manufacturing Corporation, New Brighton, MN (US)
Filed on Jun. 22, 2018, as Appl. No. 16/016,305.
Application 16/016,305 is a continuation of application No. 14/364,621, abandoned, previously published as PCT/GB2012/053113, filed on Dec. 12, 2012.
Claims priority of application No. 1121308 (GB), filed on Dec. 12, 2011.
Prior Publication US 2019/0134092 A1, May 9, 2019
Int. Cl. A61K 35/17 (2015.01); A61K 39/12 (2006.01); A61K 39/235 (2006.01); A61K 39/245 (2006.01); C12M 1/04 (2006.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 39/12 (2013.01); A61K 39/235 (2013.01); A61K 39/245 (2013.01); C12M 23/24 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55527 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2307 (2013.01); C12N 2506/11 (2013.01); C12N 2710/10034 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/18034 (2013.01); Y02A 50/30 (2018.01)] 28 Claims
 
1. An in vitro expansion process for rapid of antigen specific T cells, comprising culturing in a vessel comprising a gas permeable culture surface a population of PBMCs in a culture in the presence of an antigen, wherein the antigen is in the form of a peptide or a peptide mix relevant to a target antigen(s) and wherein the antigen is added to the culture in the range of from 1 to 500 ng per ml; wherein the culturing is performed in the presence of an exogenous cytokine wherein the cytokine is other than exogenous IL-2 and is selected from the group comprising IL-1, IL-4, IL-6, IL-7, IL-12, IL-15 and combinations thereof; wherein antigens, cytokines, media and nutrients are not added or changed after initiation of the expansion process; wherein the expansion to provide the desired population of T cells is 20 days or less; wherein the desired population of cells is a CD56− population; and wherein the peptide or peptide mix is/are not added to the culture presented on dendritic cells.